RBC Capital Positive on Kempharm (KMPH) Amid KP201 Tamper Study Results

FREE Breaking News Alerts from StreetInsider.com!

E-mail Address

StreetInsider.com Top Tickers, 10/5/2026

1. PTC
2. NVDA
3. PCVX
4. SPY
5. META
6. USO
7. MSFT
8. AMD
9. AMZN
10. ATH

Go back to RBC Capital Positive on Kempharm (KMPH) Amid KP201 Tamper Study Results

KemPharm (KMPH) Issues Positive Update on KP201/APAP in Tamper Resistance

September 30, 2015 7:33 AM EDT

KemPharm (NASDAQ: KMPH) reported positive results from three distinct studies designed to evaluate the tamper-resistant properties of its lead opioid prodrug KP201/APAP, KemPharm's prodrug of hydrocodone in combination with acetaminophen (APAP) compared to a generic hydrocodone bitartrate/APAP product (HB/APAP). The studies were designed based on feedback from the U.S. Food and Drug Administration (FDA). KemPharm believes that, together with the positive data from KemPharm's previous human abuse liability trials, these results may support FDA Category 1 abuse-deterrent language in the KP201/APAP product label, if approved by the... More